Amgen Sees Multiple Benefits From Shanghai R&D Center
This article was originally published in The Pink Sheet Daily
After more than a year of test operations, U.S. biotech giant Amgen has officially opened its Chinese research center within the campus of ShanghaiTech University.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.